Hemophilia Centre, Haemostasis Unit, Royal Free Hospital, London, UK.
Contraception. 2011 Aug;84(2):128-32. doi: 10.1016/j.contraception.2010.12.011. Epub 2011 Feb 11.
Oral anticoagulation is associated with increased bleeding complications. The aim of this study was to assess the changes in menstrual loss and pattern in women taking anticoagulant treatment.
Women on oral anticoagulant (OA) treatment at the Royal Free Hospital were interviewed and completed a questionnaire about their menstrual cycle before and after commencing oral anticoagulation treatment. They were then asked to complete a pictorial bleeding assessment chart (PBAC) during their next menstrual bleeding episode.
Fifty-three women between the ages of 20 and 50 years participated in the study. Of these, 47 women completed a PBAC. The mean duration of menstruation increased from 5 days before starting OA therapy to 7 days after the commencement of treatment. Thirty-one (66%) of the 47 women who completed the PBAC had a score that was greater than 100. The number of women who experienced flooding or clots during menstruation and intermenstrual or postcoital bleeding also increased. In total, 29 (54.7%) women changed their method of contraception during OA treatment. Seventeen women who did not want to become pregnant were not using contraception, including 10 women who were on hormonal contraception prior to starting anticoagulant therapy.
Women of reproductive age experience heavy and prolonged menstrual bleeding whilst on OA therapy. Women of reproductive age on OA therapy should be monitored for menstrual disorders to ensure that prompt and appropriate treatment is instituted. Advice about appropriate contraception should also be part of the medical care provided for these women. Barrier contraception, sterilization and progestin-only contraception are all suitable methods of contraception in this patient group.
口服抗凝剂会增加出血并发症。本研究旨在评估服用抗凝治疗的女性月经失血和模式的变化。
在皇家自由医院接受口服抗凝治疗的女性接受了访谈并在开始口服抗凝治疗前和治疗后填写了关于月经周期的问卷。然后,她们被要求在下一次月经出血期间填写图片出血评估表 (PBAC)。
53 名年龄在 20 至 50 岁之间的女性参与了这项研究。其中,47 名女性完成了 PBAC。月经期的平均持续时间从开始 OA 治疗前的 5 天增加到治疗开始后的 7 天。在完成 PBAC 的 47 名女性中,有 31 名(66%)的评分大于 100。经历月经过多或血块以及月经间或性交后出血的女性人数也有所增加。共有 29 名(54.7%)女性在 OA 治疗期间改变了避孕方法。17 名不希望怀孕的女性未使用避孕措施,其中 10 名女性在开始抗凝治疗前使用了激素避孕。
生殖年龄的女性在服用 OA 治疗时会经历大量和长时间的月经出血。应监测生殖年龄的 OA 治疗女性的月经失调,以确保及时和适当的治疗。还应为这些女性提供关于适当避孕的建议。屏障避孕、绝育和孕激素避孕都是该患者群体中合适的避孕方法。